IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0223594.html
   My bibliography  Save this article

Vaccination status of patients using anti-TNF therapy and the physicians’ behavior shaping the phenomenon: Mixed-methods approach

Author

Listed:
  • Hussain Abdulrahman Al-Omar
  • Hadeel Magdy Sherif
  • Ahmed Yaccob Mayet

Abstract

Objective: Anti-tumor necrosis factor (Anti-TNF) therapy improves the prognosis and reduces the morbidity and mortality associated with many chronic inflammatory autoimmune diseases. However, as it is linked to an increased infection risk, appropriate vaccination is required. The study aimed at investigating the vaccination status of patients receiving Anti-TNF therapy and physicians’ perceptions of and views about vaccinating these patients. Methods: A sequential explanatory mixed-methods approach was used. The study comprised a quantitative, retrospective drug utilization review for determining institutional consumption of Anti-TNF therapy and an assessment of vaccination status in patients prescribed Anti-TNF therapy to audit physicians’ adherence to Anti-TNF therapy-related vaccination recommendations. Patient data from electronic medical records (EMRs) obtained from tertiary care hospitals between September 2015 and September 2017 were used. Further, a qualitative study using a phenomenographic approach with semi-structured interviews of 12 physicians was carried out to explore the physicians’ perceptions, views, and recommendations of vaccinating patients who are undergoing Anti-TNF therapy and identifying factors that may cause poor adherence to vaccination recommendations. Results: Forty-three of 310 patients receiving Anti-TNF therapy were vaccinated. Infliximab was the most frequently prescribed agent, accounting for 96.7% of total orders. Eight of the 12 physicians stated that they were aware of vaccination guidelines and seven viewed pre–Anti-TNF therapy vaccination as essential because of the high infection risk and claimed to incorporate it in their daily practice. Barriers to adherence included ignorance of recommendations, workload, vaccine unavailability, and advanced disease state. Conclusion: Although the recommendations published by professional medical societies emphasized the importance of vaccination before initiating Anti-TNF therapy, few patients were vaccinated. Medical administration in hospitals should develop policies, procedures, and guidelines for vaccination; implement education programs for physicians and patients and procure vaccines in a timely way to improve their use.

Suggested Citation

  • Hussain Abdulrahman Al-Omar & Hadeel Magdy Sherif & Ahmed Yaccob Mayet, 2019. "Vaccination status of patients using anti-TNF therapy and the physicians’ behavior shaping the phenomenon: Mixed-methods approach," PLOS ONE, Public Library of Science, vol. 14(10), pages 1-15, October.
  • Handle: RePEc:plo:pone00:0223594
    DOI: 10.1371/journal.pone.0223594
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0223594
    Download Restriction: no

    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0223594&type=printable
    Download Restriction: no

    File URL: https://libkey.io/10.1371/journal.pone.0223594?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Christine Nguyen & Mark Bounthavong & Margaret Mendes & Melissa Christopher & Josephine Tran & Rashid Kazerooni & Anthony Morreale, 2012. "Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis," PharmacoEconomics, Springer, vol. 30(7), pages 575-593, July.
    2. James Spalding & Joel Hay, 2006. "Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis," PharmacoEconomics, Springer, vol. 24(12), pages 1221-1232, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Stefan Scholz & Thomas Mittendorf, 2014. "Modeling rheumatoid arthritis using different techniques - a review of model construction and results," Health Economics Review, Springer, vol. 4(1), pages 1-16, December.
    2. Evo Alemao & Maiwenn J Al & Annelies A Boonen & Matthew D Stevenson & Suzanne M M Verstappen & Kaleb Michaud & Michael E Weinblatt & Maureen P M H Rutten-van Mölken, 2018. "Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-18, October.
    3. Mark Bounthavong & Christine Nguyen & Margaret Mendes & Melissa Christopher & Josephine Tran & Rashid Kazerooni & Anthony Morreale, 2012. "The Authors’ Reply," PharmacoEconomics, Springer, vol. 30(10), pages 977-978, October.
    4. Sandmann, Frank G. & Franken, Margreet G. & Steenhoek, Adri & Koopmanschap, Marc A., 2013. "Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time," Health Policy, Elsevier, vol. 112(3), pages 285-296.
    5. Christine Nguyen & Mark Bounthavong & Margaret Mendes & Melissa Christopher & Josephine Tran & Rashid Kazerooni & Anthony Morreale, 2012. "Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis," PharmacoEconomics, Springer, vol. 30(7), pages 575-593, July.
    6. Anna-Liesa Lange & Philipp Otto, 2016. "Bayes’sche Statistik in der Dienstleistungsforschung [Bayesian statistics in service research]," AStA Wirtschafts- und Sozialstatistisches Archiv, Springer;Deutsche Statistische Gesellschaft - German Statistical Society, vol. 10(4), pages 247-267, December.
    7. Jaana T Joensuu & Saara Huoponen & Kalle J Aaltonen & Yrjö T Konttinen & Dan Nordström & Marja Blom, 2015. "The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review," PLOS ONE, Public Library of Science, vol. 10(3), pages 1-27, March.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0223594. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.